07 jun: Afnotering af Arkil Holding A/S
11 jun: Indre værdi af SmallCap Danmark A/S er opgjort til 10,6 kr. pr. a..
11-06-2019 02:00:00

Zealand Pharma presents dasiglucagon pivotal Phase 3 trial data at the 79th Scientific Sessions of the American Diabetes Association (ADA)

Press release – No. 14 / 2019

 

Zealand Pharma presents dasiglucagon pivotal Phase 3 trial data at the 79th Scientific Sessions of the American Diabetes Association (ADA)

  • The pivotal Phase 3 trial demonstrates that a single dose of dasiglucagon rapidly increases blood glucose levels in type 1 diabetes patients with low plasma glucose

     

  • The median time to plasma glucose recovery was 10 min following dasiglucagon injection, with 99% of patients having recovered within 15 minutes

 

Copenhagen, June 11, 2019 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, presented elaborated results from the pivotal Phase 3 study of dasiglucagon as treatment for severe hypoglycemia at the 79th Scientific Sessions of the American Diabetes Association (ADA) in San Francisco, California. Abstract No. 286-OR was presented on Monday, June 10 at 4:00 PM Pacific.

Dasiglucagon has the potential to offer millions of people living with diabetes the fastest and most effective rescue treatment for severe hypoglycemia. Dasiglucagon is a potential first-in-class soluble glucagon analog invented and developed by Zealand. It is in development in the ready-to-use HypoPal® rescue pen for easy, fast and effective treatment of severe hypoglycemia.

The results were shared as an oral presentation: Phase 3 Results for dasiglucagon as a fast and effective treatment for severe hypoglycemia, by Professor, Dr. Thomas R. Pieber, Medical University of Graz, Department of Internal Medicine, Division of Endocrinology and Diabetology. The study confirmed the efficacy and safety of dasiglucagon in the treatment of hypoglycemia in type 1 diabetes subjects. The data demonstrate superiority of dasiglucagon compared to placebo following a single subcutaneous dose administered to subjects with type 1 diabetes mellitus with insulin-induced hypoglycemia. Additionally, the study compared the glycemic response and tolerability observed after administration of dasiglucagon with that of GlucaGen®.

“The Phase 3 data in this multi-center study confirmed dasiglucagon as a potential emergency glucagon treatment with a fast recovery profile. Recovery was observed within 10 minutes for almost two-thirds of the subjects,” commented Professor, Dr. Thomas R. Pieber, Medical University of Graz, Department of Internal Medicine, Division of Endocrinology and Diabetology.

“The pivotal Phase 3 data established the fast onset of action by dasiglucagon, which we believe is of major importance when treating severe hypoglycemia,” said Adam Steensberg, Executive Vice President and Chief Medical and Development Officer at Zealand Pharma. “We believe that people living with insulin-dependent diabetes should be offered new alternatives to treating severe hypoglycemia, and we are excited about the opportunity for the dasiglucagon HypoPal® rescue pen.”

 

For further information, please contact:

Emmanuel Dulac, President and Chief Executive Officer

Tel.: +45 50 60 36 36, e-mail: edu@zealandpharma.com

Lani Pollworth Morvan, Investor Relations and Communication

Tel.: +45 50 60 37 78, e-mail: lpm@zealandpharma.com

 

Dasiglucagon (glucagon analog stable in liquid formulation) for use in other indications

Dasiglucagon is a Zealand-invented glucagon analog with a unique stability profile in a ready-to-use aqueous solution. It is also in development for two additional indications: treatment of type 1 diabetes with a next-generation artificial pancreas, and treatment for children born with a genetic mutation that causes congenital hyperinsulinism (CHI).

About t

ype 1 diabetes and hypoglycemia

People with type 1 diabetes suffer from insulin deficiency and inappropriate glucagon secretion. Both hormones are essential to ensure stable and healthy blood glucose levels. Consequently, patients must monitor and adjust their blood glucose levels to remain in proper glycemic control, as both high and low blood glucose may affect their health, both in the short and long term.

Severe hypoglycemia is an acute, life-threatening condition resulting from a critical drop in blood glucose levels associated primarily with insulin therapy. Severe hypoglycemia occurs most frequently in people with type 1 diabetes due to injecting insulin multiple times daily. It is the biggest concern for insulin-dependent patients and the most feared complication of diabetes treatment. The condition is characterized by confusion, seizures, and often loss of consciousness that can result in death if left untreated.

When a patient has a hypoglycemic event, a second person must assist in treatment. Currently marketed formulations of glucagon for the treatment of severe hypoglycemia require mixing first by the person assisting to treat and then immediate administration due to poor drug stability. Dasiglucagon is being developed to offer a stable ready-to-use rescue treatment for severe hypoglycemia.

About Zealand Pharma A/S

Zealand Pharma A/S (Nasdaq Copenhagen and New York: ZEAL) ("Zealand") is a biotechnology company focused on the discovery and development of innovative peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market. Zealand’s current pipeline of internal product candidates focus on specialty gastrointestinal and metabolic diseases. Zealand’s portfolio also includes two clinical license collaborations with Boehringer Ingelheim and pre-clinical license collaboration with Alexion Pharmaceuticals.

Zealand is based in Copenhagen (Glostrup), Denmark. For further information about the Company's business and activities, please visit www.zealandpharma.com or follow Zealand on LinkedIn or Twitter @ZealandPharma.  

 

Attachment

Z_ID_ORG_FINAL_w_name_rgb_NEW2.jpg

Relateret indhold
03 jun - 
Zealand Pharma/Bryan Garnier: Løfter kursmål til 180 kr..
24 maj - 
Zealand Pharma/SHB: Kursmålet løftes mens anbefalingen ..
22 maj - 
Onsdagens aktier: Overbevisende regnskab sendte Simcorp..
Relateret debat
16 jul - 
Jeg solgt lidt i luk i dag men det var ikke så meget.
16 jul - 
Zealand Pharma er i øvrigt oppen med 83,25% iår!
16 jul - 
Pænt luk i kurs 151 Endog med stor vulumen 26,4K i lukk..
Del

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
16 jul
ZEAL
Pænt luk i kurs 151   Endog med stor vulumen 26,4K i lukkeauktionen :-)Hvem tør være ude ....   www...
3
12 jul
ZEAL
Ja, så vafventer vi næste trin i 160
3
12 jul
ZEAL
Griner kommer ikke i 100 mere og Velo kommer ikke i 1 kr igen.. så meget godt du ikke var med😅
2
12 jul
ZEAL
Og ja, først skal den tidligere top i kurs 169 brydes ...
1
12 jul
ZEAL
Investtech d.d.: "Videre stigning til 190 eller mere er signaleret."   Men derfor kan ZP sagtens fal..
1
12 jul
ZEAL
Om ikke andet så er CFO-annonceringen og nødpen-partneraftalen tætter på!
1
12 jul
ZEAL
Dejlig stigning, men man skal aldrig sige aldrig,  sidst den var heroppe, troede man kurs 80 var umu..
1
12 jul
ZEAL
Jeg ærgrer mig over at jeg ikke har været med på stigningen. Havde ikke drømt om at kursen kunne sti..
1
12 jul
ZEAL
Det er godt at se at 150 er brudt klart!
1
12 jul
ZEAL
Kurs 151, steget 4,7 point i dag.   Er der nyt, vi små ikke ved endnu?
1

Goldman Sachs: Højere indtægter kravlede ikke med på bunden

16-07-2019 13:51:32
Indtægterne fra aktiehandel, som er et vigtigt område for den amerikanske storbank Goldman Sachs, klarede sig bedre end analytikerne havde ventet i andet kvartal. Men selv om de samlede indtægter også steg en smule, bevægede de sig ikke med ned på bundlinjen i regnskabet for kvartalet.Det skriver Bloomberg News.På bundlinjen præsenterede den New York-baserede bank et overskud på 5,81 dollar per ak..

Aktier/tendens: Stilstand på sommertynde markeder - Genmab i fokus

16-07-2019 08:06:06
Genmab kan komme i fokus tirsdag, når det amerikanske medicinalselskab Johnson & Johnson over middag kommer med regnskab for andet kvartal af 2019, da det fortæller, hvordan det globale salg af kræftmidlet Darzalex arter sig.Samlet peger det på en forholdsvis neutral åbning på det danske aktiemarked, hvis retningen skal tages efter futures for det tyske DAX-indeks, der ligger til et svagt plus.Man..

Kina fremviser sløjeste vækst i årtier midt i handelskrig

Relaterede nyheder
15-07-2019 13:28:01
Kineserne må vænne sig til, at økonomien ikke længere buldrer afsted.Tocifrede vækstrater er fortid, og det bliver mandag understreget af nye tal for landets økonomi.I andet kvartal voksede Kinas bruttonationalprodukt med 6,2 procent. Det er den sløjeste fremgang i omkring tre årtier, skriver nyhedsbureauet Reuters.De økonomiske data fra Kina er under stor bevågenhed på grund af den handelskonflik..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Trumps importafgifter tjener ikke nok til at dække omkostninger
2
Genmab: Johnson & Johnson salg af Darzalex overrasker
3
Vestas lander ordre på 415 MW i Saudi Arabien - NY
4
Vestas: Tabel med ordrer annonceret i 2019
5
Genmab/Sydbank: Dazalex-salget uden for USA overrasker

Relaterede aktiekurser

Zealand Pharma A/S 151.00 2,0% Stigning i aktiekurs
Zealand Pharma Aktiesels.. 151.00 2,0% Stigning i aktiekurs

Copyright Berlingske Media 2019  Handelsbetingelser  |  Cookiedeklaration  |  Cookie- og Privatlivspolitik  |  Ophavsret og vilkår
Aktieinformation leveres af Morningstar.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
17. juli 2019 08:36:59
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20190703.1 - EUROWEB7 - 2019-07-17 08:36:59 - 2019-07-17 08:36:59 - 1 - Website: OKAY